Stapokibart (CM310) in patients with uncontrolled seasonal allergic rhinitis (PHECDA): Rationale and design of a multicentre, randomized, double-blind, placebo-controlled study
Authors
Jingyun Li (ORCID: https://orcid.org/0000-0001-8066-4648)
Chengshuo Wang (ORCID: https://orcid.org/0000-0003-0646-5135)
Luo Zhang (ORCID: https://orcid.org/0000-0002-0910-9884)
Stapokibart (CM310) in patients with uncontrolled seasonal allergic rhinitis (PHECDA): Rationale and design of a multicentre, randomized, double-blind, placebo-controlled study
Jingyun Li, Chengshuo Wang, Luo Zhang, Yuan Zhang et al.
Citations
3 citations
Journal
Asia Pacific Allergy
Topics
Allergic Rhinitis and Sensitization
Field-Weighted Citation Impact (FWCI)
4.87
article
Stapokibart (CM310) in patients with uncontrolled seasonal allergic rhinitis (PHECDA): Rationale and design of a multicentre, randomized, double-blind, placebo-controlled study
Jingyun Li, Chengshuo Wang, Luo Zhang, Yuan Zhang, Menglin Wang
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
Asia Pacific AllergyVol. 15(1)
Institutions
Beijing Tongren Hospital (CN), Ministry of Education of the People's Republic of China (CN), Capital Medical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN)